- Tong Ren Tang reported a net income of 1.53 billion yuan for its fiscal year.
- The company’s revenue for the same period was 18.60 billion yuan.
- There were 15 buy recommendations for Tong Ren Tang’s stock.
- Analysts issued 1 hold recommendation.
- There was 1 sell recommendation reported.
A look at Beijing Tongrentang Co A Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tongrentang Co A, a company specializing in Chinese traditional medicines and medicinal wines, has received a moderate to high overall outlook as per the Smartkarma Smart Scores assessment. With strong scores in Dividend, Growth, and Resilience factors, the company shows potential for sustainable growth and stable performance in the long term.
However, Beijing Tongrentang Co A lags in terms of Value and Momentum scores, indicating that it may not currently be undervalued and might be experiencing lower short-term market momentum. Investors looking for a company with promising dividends, growth prospects, and resilience in the industry might find Beijing Tongrentang Co A an appealing long-term investment option based on the provided scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
